Cancer Patients Hide Their Use of Complementary and Alternative Treatments From Their Doctors
Posted on: Sunday, 16 October 2005, 12:00 CDT
DENVER, Oct. 16 /U.S. Newswire/ -- Although almost half (48 percent) of cancer patients treated with chemotherapy and radiation are using at least one type of complementary and alternative medical therapy (CAM) treatment, a majority of them (75 percent) don't tell their doctor, even while receiving conventional cancer treatment, according to a study presented Oct. 16, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
The study shows that CAM use is almost twice as prevalent among patients treated by only chemotherapy (65 percent), compared to those treated by only radiation (35 percent). Most (88 percent) of patients are satisfied with using CAM as a cost- effective method of cancer treatment and use an average of two CAM treatments, with vitamin, herbal and botanical supplements being the most popular therapies. Only a little more than a third (36 percent) of them say their doctors were an important source of information on CAM.
"This study shows the significant lack of communication between patients and their doctors about the use of complementary and alternative medicines, like vitamins and herbs," said Neha Vapiwala, M.D., lead author of the study and a radiation oncologist at the University of Pennsylvania in Philadelphia. "It's important for doctors to know about their patients' CAM use and to understand patients' reasons for using it, so that they can better tailor and optimize treatment regimens and improve patient quality of life during radiation and/or chemotherapy."
The study asked 487 cancer patients at a clinic and over the Internet about their CAM use from July to September, 2004.
For more on radiation therapy, visit www.rtanswers.org.
The study, "Initiation of Complementary and Alternative Medical Therapies (CAM) by Cancer Patients (Pts) During Radiation Therapy (RT)," will be available for poster viewing starting at 10 a.m. on Sunday, Oct. 16. To get a copy of the abstract or to speak to the lead author of the study, Neha Vapiwala, M.D., call Beth Bukata or Nick Lashinsky Oct. 16-20 in the ASTRO Press Room at the Colorado Convention Center at 303-288-8454 or 303-228- 8455; or by email bethb(At)astro.org, nickl(At)astro.org.
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.
http://www.usnewswire.com
Source: U.S. Newswire
Related Articles
- Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
- ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients With Advanced Endometrial Cancer
- RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- Sosei Initiates Phase III Studies for Cancer Pain Treatment
- Breast Cancer Patients May Be Offered Chemo-Free Treatment
- Avantogen Oncology Inc. Announces Preliminary Results of a Dose Ranging Study of RP101 in Combination With Gemcitabine Chemotherapy in Patients With Advanced Pancreatic Cancer
- AmpliMed Initiates Phase I Clinical Study of Benzimate in Patients With Advanced Refractory Cancer
- City Cancer Patients Still Waiting Too Long for Treatment Not Enough Sufferers Seen Inside Scotland's Two-Month Limit
- Homoeopathy Benefits Could Be All in the Patient's Mind Study Questions Effectiveness of Treatment
- Editorial: Tailoring Treatment to Patients With Early Breast Cancer - Can We Deliver?
User Comments (0)

RSS Feeds